These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37070927)

  • 1. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
    Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
    Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in RET-targeted cancer therapy.
    Hu X; Khatri U; Shen T; Wu J
    Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
    Shen T; Hu X; Liu X; Subbiah V; Mooers BHM; Wu J
    NPJ Precis Oncol; 2021 Jun; 5(1):48. PubMed ID: 34099825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET kinase alterations in targeted cancer therapy.
    Liu X; Hu X; Shen T; Li Q; Mooers BHM; Wu J
    Cancer Drug Resist; 2020; 3(3):472-481. PubMed ID: 35582449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
    Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
    Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
    Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
    Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
    NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
    Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
    Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
    Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
    Hu X; Liu X; Khatri U; Wu J
    Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 19. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.